Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BioFocus Extends its Collaboration with The Michael J. Fox Foundation

Published: Thursday, April 18, 2013
Last Updated: Thursday, April 18, 2013
Bookmark and Share
BioFocus has extended its collaboration agreement for Parkinson’s Research.

BioFocus has announced that it has extended its collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research, a not-for-profit organization focused on developing therapies for Parkinson’s disease.

Based on the success of the project to date, BioFocus will continue the optimization of agents for disease specific biomarkers.

“We have worked with The Michael J. Fox Foundation since 2011 to identify and optimize a-synuclein imaging agents, and are delighted that the progress supports an extension to this collaboration,” said Dr Chris Newton, Managing Director, BioFocus.

Dr Newton continued, “The program will utilize BioFocus' leading biology and chemistry platforms, and will capitalize on the company’s highly experienced teams and state-of-the-art technologies.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

BioFocus Signs Integrated Drug Discovery Collaboration with Boehringer Ingelheim
Under the terms of the agreement, BioFocus will apply its drug discovery services to an undisclosed target within Boehringer Ingelheim’s drug discovery portfolio.
Thursday, November 21, 2013
BioFocus Signs Agreement with Biogen Idec
The 3-year collaboration will focus on the identification and validation of novel targets in scleroderma.
Tuesday, November 12, 2013
BioFocus Signs Agreement with Aviva Investors
Pre-let agreement for construction of new laboratory and HQ building at Chesterford Research Park.
Thursday, September 05, 2013
BioFocus Receives Rapid Response Innovation Award from The Michael J. Fox Foundation
Grant will support the development of a novel Parkinson’s disease cell model.
Tuesday, June 25, 2013
BioFocus Launches Academic Engagement Initiative
Aim of the initiative is to identify the best new therapeutic strategy ideas from academic groups.
Wednesday, May 01, 2013
Peter Rehse joins BioFocus as Senior Director, Structural Biology
BioFocus today announced that Dr. Peter Rehse has joined the company and will be based at Chesterford Park, near Cambridge, UK.
Monday, February 11, 2013
BioFocus Announces Agreement with ChanTest
BioFocus expands ion channel offering.
Thursday, February 07, 2013
BioFocus Achieves Milestone in its Drug Discovery Collaboration with UCB
Discovery milestone triggers payment from UCB and demonstrates BioFocus’ ability to support its clients.
Tuesday, December 04, 2012
BioFocus and Ono Sign a Drug Discovery Agreement
The collaboration agreement between Galapagos NV’s service division, BioFocus, and Ono Pharmaceutical Co., Ltd. will focus on discovering novel drugs in the field of CNS disorders.
Monday, September 03, 2012
BioFocus and Activiomics Announces Strategic Alliance
BioFocus expands its drug discovery offering with proteomics technology from Activiomics.
Thursday, July 26, 2012
BioFocus and Argenta Announce Drug Discovery Collaboration
Collaboration with AstraZeneca in respiratory and inflammatory disease.
Thursday, March 15, 2012
Almirall and BioFocus enter Research Alliance
Three-year integrated drug discovery alliance aims to identify drug development candidates for treating respiratory disease.
Wednesday, January 25, 2012
Argenta and BioFocus Announce Two-Year Extension Of Drug Discovery Collaboration with Genentech
Total potential value of the contract extension is up to £21.5 million (€23.4 million).
Monday, August 22, 2011
BioFocus and InterMed Discovery Announce Marketing Collaboration
The collaboration will offer enhanced natural product discovery to the pharmaceutical, animal health, and agrochemical industries.
Wednesday, August 03, 2011
BioFocus and InterMed Discovery Announce Marketing Collaboration
IMD will make natural product screening libraries available and provide follow-on services to BioFocus.
Wednesday, July 20, 2011
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Transporting Microscopic Cargo Between Human Cells
Scientists have developed a virus-inspired delivery system for material transport between cells.
Metabolite Promotes Cancer Cell Transformation
Researchers have identified a metabolite that promotes cancer cell transformation and colorectal cancer spread.
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
Bird Flu Confirmed in the Netherlands
An outbreak of H5 avian influenza was confirmed in the Flevoland province of the Netherlands.
Pasteurised Bacterium Reduces Obesity and Diabetes
Researchers have discovered that an intestinal bacterium provides a lasting effect on the intestinal barrier.
Turning Off Asthma Attacks
Researchers discover a critical cellular “off” switch for the inflammatory immune response that causes asthma attacks.
Zika’s Entry Points
Discovery shows Zika infection of neural progenitor cells occurs regardless of AXL production, which was thought to be the main vector for the virus.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!